PROM1 and ovarian carcinoma: To determine whether primary CD133+ CSLCs could also express IL-23 and IL-23R, we utilized immunofluorescence to investigate the expression of CD133, IL-23p19 and IL-23R on in situ ovarian cancer tissue samples.